A Study of LY03005 vs Pristiq

NCT03733574 | Completed Phase 1 FDA Drug

• 1 other identifier: LY03005/CT-USA-106
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.

Conditions

Major Depressive Disorder

Keywords

Depressive Disorder, Major; Depressive Disorder; Mood Disorders; Mental Disorders; Desvenlafaxine Succinate; Serotonin and Noradrenaline Reuptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Physiological Effects of Drugs; Antidepressive Agents; Psychotropic Drugs

Outcome Measures

Primary Outcomes (1)

• concentration-time curve (AUC)

  Plasma ODV area under the concentration-time curve (AUC)

  15 days

Study Arms (2)

LY03005 cross-over to Pristiq® (Desvenlafaxine)

EXPERIMENTAL

Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).

Drug: LY03005; Drug: Pristiq

Pristiq® (Desvenlafaxine) cross-over to LY03005

EXPERIMENTAL

Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005

Drug: LY03005; Drug: Pristiq

Interventions

LY03005 DRUG

Drug: LY03005 80 mg, oral tablets, single dose

LY03005 cross-over to Pristiq® (Desvenlafaxine); Pristiq® (Desvenlafaxine) cross-over to LY03005

Pristiq DRUG

Drug: Pristiq 50 mg, oral tablets, single dose

Also known as: Desvenlafaxine

LY03005 cross-over to Pristiq® (Desvenlafaxine); Pristiq® (Desvenlafaxine) cross-over to LY03005

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Capable of giving informed consent and complying with trial procedures;
• Male and female subjects between the ages of 18 and 50 years, inclusive;
• Considered healthy by the Investigator based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;
• Nonsmoker, defined as not having smoked or used any form of tobacco for at least 6 months before Screening based on subject report;
• Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg;
• Willing and able to adhere to trial procedures and to be confined at the clinical research unit (CRU).
• All female subjects (childbearing potential and non-childbearing potential) must have a negative serum pregnancy test result at Screening. In addition, female subjects must meet 1 of the following 3 conditions: (i) postmenopausal for at least 12 months without an alternative medical cause, (ii) surgically sterile (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal occlusion) based on subject report, or (iii) if of childbearing potential and heterosexually active, practicing or agree to practice a highly effective method of contraception. Highly effective methods of birth control include an intrauterine device (IUD), intrauterine hormone-releasing system (IUS), and contraceptives (oral, skin patches, or implanted or injectable products) using combined or progestogen-only hormonal contraception associated with inhibition of ovulation. A vasectomized male partner is an acceptable birth control method if the vasectomized partner is the sole sexual partner of the female subject and the vasectomized partner has received medical confirmation of surgical success.
• Highly effective methods of birth control must be used for at least 14 days prior to study drug dosing, through the end of study (EOS) visit or early termination, and for a minimum of 1 month after the last dose of study drug to minimize the risk of pregnancy. Sexually active, fertile, male subjects must be willing to use acceptable contraception methods (such as double-barrier methods of a combination of male condom with either cap, diaphragm, or sponge with spermicide) from the first dose of study drug through the EOS visit or early termination, and for a minimum of 1 month after the last dose of study drug.

You may not qualify if:

• Clinically significant past medical history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric (including life-long history of depression and/or anxiety), renal, hepatic, bronchopulmonary, neurologic, immunologic, ophthalmological, or lipid metabolism disorders; or drug hypersensitivity; or any other condition that in the judgement of the Investigator will affect the trial results or the subject's safety;
• History of suicide attempt in the past 12 months and/or seen by the Investigator as having a significant history of risk of suicide or homicide;
• History or presence of malignancy other than adequately treated and cured basal cell carcinoma or squamous cell carcinoma (skin cancer);
• Clinically relevant illness within 1 month prior to Screening or at Screening that may interfere with the conduct of this trial;
• Medically uncontrolled high blood pressure with mean systolic blood pressure \>140 mmHg or mean diastolic blood pressure \>90 mmHg at Screening after 3 measurements (after at least 5 minutes of rest in a seated position);
• History of Long QT Syndrome (LQTS) or a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms);
• Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
• History of seizure (history of febrile seizure allowed);
• Hospital admission or major surgery within 30 days prior to Screening;
• Participation in any other investigational drug trial within 30 days prior to Screening;
• History of prescription drug abuse or illicit drug use within 6 months prior to Screening;
• History of alcohol abuse according to medical history within 6 months prior to Screening;
• Positive screen for alcohol and/or drugs of abuse;
• Tobacco use within 6 months prior to Screening based on positive nicotine screen;
• History of intolerance or hypersensitivity to ODV or medicines containing ODV or its precursor venlafaxine;

Sponsors & Collaborators

• Luye Pharma Group Ltd.: lead

Study Sites (1)

Pharmaron CPC, Inc.

Baltimore, Maryland, 21201, United States

Location

Related Links

• Drug information
• Desvenlafaxine
• Desvenlafaxine Succinate
• U.S. FDA Resources
• Pristiq (Desvenlafaxine) Label - FDA

MeSH Terms

Conditions

Depressive Disorder, Major; Depressive Disorder; Mood Disorders; Mental Disorders

Interventions

Desvenlafaxine Succinate

Intervention Hierarchy (Ancestors)

Cyclohexanols; Hexanols; Fatty Alcohols; Alcohols; Organic Chemicals; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Lipids

Study Officials

• Amy Sun, MD, PhD, MBA

  Luye Pharma Group Ltd.

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2018
• First Posted: November 7, 2018
• Study Start: June 19, 2018
• Primary Completion: July 17, 2018
• Study Completion: July 26, 2018
• Last Updated: November 9, 2018

Record last verified: 2018-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)